Dan Weiner, is the co-founder and managing partner of RevelOne, a marketing talent and strategy firm for technology companies.

[6] His younger son is Ron Weiner, a television writer with credits such as Silicon Valley (TV series) and 30 Rock.

[2][7] Weiner majored in philosophy as an undergraduate at Dartmouth College (1962-1965), leaving after three years to attend medical school.

It is currently in its 8th edition, now authored by Alex Rae Grant, MD and entitled Weiner and Levitt's Neurology for the House Officer.

He then returned to Harvard Medical School to take a research position in the laboratory of Bernard N. Fields where he studied viral host interactions using the reovirus model system.

In 1985, Weiner was awarded an endowed chair from the Kroc Foundation of Santa Inez California for his study of MS with a gift of $1M to the Harvard Medical School.

The major focus of Weiner's career has been the study of MS, which he began in 1972 as a resident in neurology at the Peter Bent Brigham Hospital in Boston.

In 1983, he alongside Stephen L. Hauser, now Director, Weill Institute for Neurosciences and Professor of Neurology at University of California, San Francisco, published a seminal article on the treatment of MS in The New England Journal of Medicine.

This demonstrated in a controlled trial a profound effect of the immunosuppressant and chemotherapy drug cyclophosphamide in stopping active, progressive MS.[12] The article introduced the timed 25-foot walk (ambulation index) that subsequently has become a classic clinical measure in MS.

Weiner established the CLIMB Study (Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women's Hospital).

Weiner has pioneered the basic investigation and application of oral tolerance and mucosal immunology for the treatment of autoimmune and inflammatory diseases.

In 2021, he initiated human trials of a nasal vaccine for the treatment of Alzheimer's disease in which blood monocytes are triggered to clear amyloid from the brain.

Susan Quinn, a writer known for her biography of Marie Curie, chronicled Weiner's journey with Autoimmune, Inc in a book entitled, Human Trials: Scientists, Investors, and Patients in the Quest for a Cure[15].

[16] Based on Weiner's research, Tilos Therapeutics was formed in 2016 and is developing the treatment of cancer using a monoclonal antibody directed against LAP which a new checkpoint inhibitor that targets TGF-beta and regulatory T cells.

[27] In 2007, Weiner published Curing MS: How Science is Solving the Mysteries of Multiple Sclerosis (Crown: New York).

In his book, Weiner likens the brain to a crime scene, showing readers how “clues” point to causes and suggest paths to a cure.